# Real-Life Evidence on Stroke Prevention in SPAF

> **NCT02485873** · — · COMPLETED · sponsor: **Bayer** · enrollment: 8607 (actual)

## Conditions studied

- Atrial Fibrillation (Prevention of Stroke)

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Vitamin K antagonists

## Key facts

- **NCT ID:** NCT02485873
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 8607 (ACTUAL)
- **Last updated:** 2015-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485873, "Real-Life Evidence on Stroke Prevention in SPAF". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT02485873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*